Evinova and Bristol Myers Squibb Partner to Use AI in Clinical Development
Tuesday, February 10, 2026
Evinova has entered into a strategic agreement with Bristol Myers Squibb to support the optimisation of clinical trials using artificial intelligence. As part of the collaboration, Bristol Myers Squibb will use the Cost Optimizer module within Evinova’s Study Designer across its global clinical development portfolio.
The agreement focuses on improving decision-making in clinical trials through AI-driven insights. The platform is expected to help identify productivity gains, support more efficient trial designs, and improve experiences for both trial sites and patients, while also helping to speed up drug development.
Evinova’s AI-native clinical development platform uses advanced artificial intelligence to support study design, improve collaboration, and enable smooth digital data flow in line with USDM standards. The platform also includes built-in controls to ensure the responsible use of AI. It is used at a global scale and has delivered significant long-term cost savings for customers.
In addition to trial optimisation tools, Evinova offers a Unified Trial Solution that connects key study components into a single digital experience for sponsors, sites and patients. The solution combines electronic clinical outcome assessments with telehealth services and connected devices for remote patient monitoring. This approach supports better toxicity management, reduces operational challenges, and enables the collection of high-quality data for new trial endpoints and innovative study designs.
Evinova’s platform has been shown to shorten development timelines, lower costs, improve data quality, and enhance patient engagement. These improvements aim to reduce the impact of adverse events and support better overall outcomes in clinical research.
Source: businesswire.com
